Steven Burstein, MD
Interventional Cardiology · Los Angeles, CANPI 1386638153
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $264,900 of the $352,137 with a category attached, or 75.2%. 15 manufacturers reported payments, led by Lifewatch Services Inc at 43.8% of the total. Reporting peaked in 2019 at $228,252 and has fallen 98.9% since, to $2,513 in 2025. Among interventional cardiology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 306 payments — averaging $1150.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lifewatch Services Inc$154K
- Edwards Lifesciences$141K
- Boston Scientific$25K
- Philips North America LLC$12K
- Medtronic$11K
- Abbott$6K
- plus $4K from 9 others
Across 37 payments — averaging $4380.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$123K
- Abbott$28K
- Boston Scientific$10K
What the payments were for
- Consulting fees$264,90075%
- Speaking & faculty fees$70,38820%
- Grants$1000%
- Travel & lodging$5,4112%
- Food & beverage$11,3393%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lifewatch Services Inc | 1 | $154,331 |
| Edwards Lifesciences | 132 | $140,594 |
| Boston Scientific | 52 | $24,715 |
| Philips North America LLC | 3 | $11,891 |
| Medtronic(2 entities) | 34 | $11,045 |
| Abbott | 58 | $5,663 |
| Bard Peripheral Vascular, Inc. | 1 | $2,400 |
| Shockwave Medical, Inc | 5 | $722 |
| Abiomed | 6 | $271 |
| Recor Medical Inc | 5 | $241 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $125 |
| Novartis | 5 | $73 |
| Biosense Webster, Inc. | 1 | $31 |
| Inari Medical, Inc. | 1 | $24 |
| Biotronik Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cardiac Monitoring Suite$154,331
- Edwards SAPIEN 3 Transcatheter Heart Valve$137,980
- (7999) SRC Undivided$11,850
- GENERAL - STRUCTURAL HEART$9,608
- COREVALVE EVOLUT R$9,352
- Watchman$6,200
- GENERAL VASCULAR ACCESS$4,385
- GENERAL - THERAPIES$1,887
- Tricuspid Valve Repair System$1,500
- Mitra Clip system$690
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$687
- MitraClip$558
- CARDIOMEMS$489
- SAPIEN 3 Ultra RESILIA$388
- Micra$350
- PASCAL$344
- CROSSBOSS$343
- CoreValve Evolut$275
- GENERAL ATHERECTOMY$175
- CardioMEMS HF System$165
How this compares
$352,137 in reported general payments places this provider in the 95th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 113 | $115,170 |
| EntrestoSacubitril/Valsartan | 52 | $55,071 |
| Repatha SureclickEvolocumab | 62 | $49,790 |
| JardianceEmpagliflozin | 12 | $15,715 |
| Repatha SyringeEvolocumab | 12 | $12,720 |
| XareltoRivaroxaban | 12 | $9,564 |
| Praluent PenAlirocumab | 15 | $8,153 |
| Ranolazine ErRanolazine | 69 | $7,266 |
| Droxidopa | 13 | $2,931 |
| Valsartan | 88 | $2,052 |
| ClopidogrelClopidogrel Bisulfate | 198 | $1,829 |
| Carvedilol | 127 | $1,524 |
| Atorvastatin Calcium | 195 | $1,382 |
| Amiodarone Hcl | 22 | $1,297 |
| Rosuvastatin Calcium | 130 | $1,136 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $73 | $55,07152 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in Los Angeles
- Evan ZahnLos Angeles$632K
- Jubin JosephLos Angeles$217K
- Ali NsairLos Angeles$162K
- Ray MatthewsLos Angeles$159K
- Daniel AsemotaLos Angeles$155K
- Christina EconomidesLos Angeles$150K
- Aakriti GuptaLos Angeles$139K
- Matthew Pricela Jolla$2.3M
- Frederick St GoarMountain View$2.2M
- Saibal KarThousand Oaks$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.